Erik S G Stroes

List of Publications by Year
in descending order

175 papers	23,528 citations	19657 61 h-index	7950 149 g-index
180 all docs	180 docs citations	180 times ranked	20842 citing authors

#	Article	IF	Citations
1	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. European Heart Journal, 2022, 43, 830-833.	2.2	92
2	Finding very high lipoprotein(a): the need for routine assessment. European Journal of Preventive Cardiology, 2022, 29, 769-776.	1.8	29
3	Working towards full eradication of lipid-driven cardiovascular risk?. Netherlands Heart Journal, 2022, 30, 15-24.	0.8	2
4	The challenge of choosing in cardiovascular risk management. Netherlands Heart Journal, 2022, 30, 47-57.	0.8	5
5	Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis. Heart, 2022, 108, 61-66.	2.9	18
6	Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia. Atherosclerosis, 2022, 340, 61-67.	0.8	6
7	Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. Atherosclerosis, 2022, 341, 43-49.	0.8	28
8	Response to: Correspondence on "Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis" by Pantelidis et al. Heart, 2022, 108, 576-577.	2.9	0
9	Targeted proteomics improves cardiovascular risk prediction in secondary prevention. European Heart Journal, 2022, 43, 1569-1577.	2.2	55
10	Lipoprotein(a) Induces Vesicular Cardiovascular Calcification Revealed With Single-Extracellular Vesicle Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 778919.	2.4	12
11	Reduced baroreflex sensitivity and increased splenic activity in patients with severe obstructive sleep apnea. Atherosclerosis, 2022, 344, 7-12.	0.8	1
12	Lipoprotein(a): An underestimated inflammatory mastermind. Atherosclerosis, 2022, 349, 101-109.	0.8	32
13	Considerations for routinely testing for high Lp(a). Current Opinion in Lipidology, 2022, 33, 213-218.	2.7	4
14	Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study. BMJ Open, 2021, 11, e045482.	1.9	35
15	Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease. Scientific Reports, 2021, 11, 4126.	3.3	2
16	From evidence to practice: development of web-based Dutch lipid reference values. Netherlands Heart Journal, 2021, 29, 441-450.	0.8	6
17	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 264-275.	11.4	109
18	Monocyte-Chemoattractant Protein-1 Levels in Human Atherosclerotic Lesions Associate With Plaque Vulnerability. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2038-2048.	2.4	48

#	Article	IF	Citations
19	Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis, 2021, 327, 13-17.	0.8	35
20	Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic LPA Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses. Circulation Genomic and Precision Medicine, 2021, 14, e003271.	3.6	11
21	Lipoprotein(a) Measurement in Clinical Practice. JAMA Internal Medicine, 2021, 181, 1138.	5.1	0
22	Impact of cholesterol on proinflammatory monocyte production by the bone marrow. European Heart Journal, 2021, 42, 4309-4320.	2.2	31
23	PCSK9 Inhibition and Oxidized Phospholipids. Journal of the American College of Cardiology, 2021, 78, 1288-1289.	2.8	6
24	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€"a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	2.2	303
25	Next-generation sequencing to confirm clinical familial hypercholesterolemia. European Journal of Preventive Cardiology, 2021, 28, 875-883.	1.8	23
26	Sympathetic activation by lower body negative pressure decreases kidney perfusion without inducing hypoxia in healthy humans. Clinical Autonomic Research, 2020, 30, 149-156.	2.5	4
27	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of ⁸⁹Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. Bioconjugate Chemistry, 2020, 31, 360-368.	3.6	22
28	Dynamic magnetic resonance measurements of calf muscle oxygenation and energy metabolism in peripheral artery disease. Journal of Magnetic Resonance Imaging, 2020, 51, 98-107.	3.4	13
29	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. European Journal of Preventive Cardiology, 2020, 27, 593-603.	1.8	224
30	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	2.2	4,871
31	Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial. Diabetologia, 2020, 63, 597-610.	6.3	60
32	The therapeutic age paradox coming to an end. European Heart Journal, 2020, 41, 2259-2261.	2.2	2
33	Netrin-1 and the Grade of Atherosclerosis Are Inversely Correlated in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 462-472.	2.4	17
34	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. Atherosclerosis, 2020, 311, 13-19.	0.8	21
35	Common gene variants in ASGR1 gene locus associate with reduced cardiovascular risk in absence of pleiotropic effects. Atherosclerosis, 2020, 306, 15-21.	0.8	9
36	Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability. Frontiers in Cell and Developmental Biology, 2020, 8, 581641.	3.7	29

#	Article	IF	Citations
37	BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes. Clinical Epigenetics, 2020, 12, 166.	4.1	25
38	Next-generation sequencing to confirm clinical familial hypercholesterolemia. European Journal of Preventive Cardiology, 2020, , 204748732094299.	1.8	12
39	Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease. Circulation, 2020, 142, 1996-1998.	1.6	81
40	Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema. New England Journal of Medicine, 2020, 383, 1242-1247.	27.0	28
41	Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy. Stroke, 2020, 51, 2972-2982.	2.0	16
42	Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. European Heart Journal, 2020, 41, 3998-4007.	2.2	68
43	Gene-based therapy in lipid management: the winding road from promise to practice. Expert Opinion on Investigational Drugs, 2020, 29, 483-493.	4.1	20
44	Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a). Lipids in Health and Disease, 2020, 19, 91.	3.0	4
45	A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. Cardiology and Therapy, 2020, 9, 447-465.	2.6	6
46	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. Circulation, 2020, 142, 621-642.	1.6	232
47	Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. Expert Review of Cardiovascular Therapy, 2020, 18, 355-361.	1.5	25
48	Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. Circulation Research, 2020, 126, 1346-1359.	4.5	96
49	The dedicated â€œLp(a) clinicâ€• A concept whose time has arrived?. Atherosclerosis, 2020, 300, 1-9.	0.8	52
50	Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Diseaseâ€"Free Survival, and Mortality Risk. JAMA Network Open, 2020, 3, e200129.	5.9	27
51	Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). European Heart Journal, 2020, 41, 2262-2271.	2.2	65
52	Surmounting the endothelial barrier for delivery of drugs and imaging tracers. Atherosclerosis, 2020, 315, 93-101.	0.8	4
53	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2019, 381, 531-542.	27.0	359
54	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 1780.	7.4	314

#	Article	IF	Citations
55	PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes inÂCirculating Inflammatory Markers. JACC: Cardiovascular Imaging, 2019, 12, 2571-2573.	5.3	44
56	Treatment with Statins Does Not Revert Trained Immunity in Patients with Familial Hypercholesterolemia. Cell Metabolism, 2019, 30, 1-2.	16.2	130
57	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With AorticÂStenosis. Journal of the American College of Cardiology, 2019, 73, 2150-2162.	2.8	187
58	Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. Journal of the American Heart Association, 2019, 8, e011662.	3.7	292
59	Pharmaceutical Development and Safety Evaluation of a GMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases. Marine Drugs, 2019, 17, 699.	4.6	22
60	Predictive value of targeted proteomics for coronary plaque morphology in patients with suspected coronary artery disease. EBioMedicine, 2019, 39, 109-117.	6.1	42
61	Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. European Heart Journal, 2019, 40, 2775-2781.	2.2	95
62	FISHing for the Miracle of Eicosapentaenoic Acid. New England Journal of Medicine, 2019, 380, 89-90.	27.0	66
63	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019, 139, 1483-1492.	1.6	533
64	Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nature Biomedical Engineering, 2018, 2, 279-292.	22.5	94
65	Inflammation-Sensitive Myosin-X Functionally Supports Leukocyte Extravasation by Cdc42-Mediated ICAM-1â€"Rich Endothelial Filopodia Formation. Journal of Immunology, 2018, 200, 1790-1801.	0.8	28
66	PCSK9 inhibitors in clinical practice: Delivering on the promise?. Atherosclerosis, 2018, 270, 205-210.	0.8	45
67	CCR2 expression on circulating monocytes is associated with arterial wall inflammation assessed by 18F-FDG PET/CT in patients at risk for cardiovascular disease. Cardiovascular Research, 2018, 114, 468-475.	3.8	43
68	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 119-127.	3.0	17
69	Prolonged hematopoietic and myeloid cellular response in patients after an acute coronary syndrome measured with 18F-DPA-714 PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1956-1963.	6.4	7
70	Effect of Vegan Fecal Microbiota Transplantation on Carnitineâ€•and Cholineâ€Derived Trimethylamineâ€Nâ€Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome. Journal of the American Heart Association, 2018, 7, .	3.7	164
71	Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. European Heart Journal, 2018, 39, 3521-3527.	2.2	44
72	Characterization of immune cell, endothelial, and renal responses upon experimental human endotoxemia. Journal of Pharmacological and Toxicological Methods, 2018, 89, 39-46.	0.7	16

#	Article	IF	Citations
73	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. Data in Brief, 2018, 21, 1334-1336.	1.0	4
74	From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. Cardiovascular Research, 2018, 114, 1714-1727.	3.8	63
75	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. European Journal of Preventive Cardiology, 2018, 25, 948-955.	1.8	46
76	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. European Heart Journal, 2018, 39, 2589-2596.	2.2	100
77	Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cardiovascular Drugs and Therapy, 2018, 32, 365-372.	2.6	19
78	Consistent LDLâ€Ć response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clinical Cardiology, 2018, 41, 1328-1335.	1.8	25
79	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an â€œFCS scoreâ€. Atherosclerosis, 2018, 275, 265-272.	0.8	131
80	Diagnostic algorithm for familial chylomicronemia syndrome. Atherosclerosis Supplements, 2017, 23, 1-7.	1.2	94
81	How common are foot problems among individuals with diabetes? Diabetic foot ulcers in the Dutch population. Diabetologia, 2017, 60, 1271-1275.	6.3	20
82	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. Atherosclerosis Supplements, 2017, 26, 16-24.	1.2	24
83	Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 969-975.	2.4	85
84	Systematic Review and Network Metaâ€Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. Journal of the American Heart Association, 2017, 6, .	3.7	61
85	Nile Red Quantifier: a novel and quantitative tool to study lipid accumulation in patient-derived circulating monocytes using confocal microscopy. Journal of Lipid Research, 2017, 58, 2210-2219.	4.2	20
86	The maturation of a â€˜neuralâ€“hematopoieticâ€™ inflammatory axis in cardiovascular disease. Current Opinion in Lipidology, 2017, 28, 507-512.	2.7	8
87	Arterial and Cellular Inflammation in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 1278-1285.	6.1	46
88	PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. European Heart Journal, 2017, 38, 1584-1593.	2.2	141
89	Intestinal Ralstonia pickettii augments glucose intolerance in obesity. PLoS ONE, 2017, 12, e0181693.	2.5	53
90	Impact of the B Cell Growth Factor APRIL on the Qualitative and Immunological Characteristics of Atherosclerotic Plaques. PLoS ONE, 2016, 11, e0164690.	2.5	9

#	Article	IF	Citations
91	Increased haematopoietic activity in patients with atherosclerosis. European Heart Journal, 2016, 38, ehw246.	2.2	62
92	Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice. Npj Biofilms and Microbiomes, 2016, 2, 16009.	6.4	159
93	Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. Cardiovascular Drugs and Therapy, 2016, 30, 297-304.	2.6	23
94	Magnetic Resonance Imagingâ€"Derived Renal Oxygenation and Perfusion During Continuous, Steadyâ€State Angiotensinâ€II Infusion inÂHealthy Humans. Journal of the American Heart Association, 2016, 5, e003185.	3.7	23
95	Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1463-1470.	3.3	32
96	Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 2016, 134, 611-624.	1.6	396
97	Carotid arterial wall inflammation in peripheral artery disease is augmented by type 2 diabetes: a cross-sectional study. BMC Cardiovascular Disorders, 2016, 16, 237.	1.7	7
98	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160Âmg/dl or Higher. Cardiovascular Drugs and Therapy, 2016, 30, 473-483.	2.6	160
99	Thresholds for Arterial Wall Inflammation Quantified by 18F-FDG PET Imaging. JACC: Cardiovascular Imaging, 2016, 9, 1198-1207.	5.3	81
100	Efficacy and Safety of Alirocumab 150Âmg Every 4ÂWeeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Journal of the American Heart Association, 2016, 5, .	3.7	71
101	Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy. Annals of the Rheumatic Diseases, 2016, 75, 1848-1851.	0.9	26
102	Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study. Arthritis Research and Therapy, 2016, 18, 115.	3.5	30
103	HDL infusion for the management of atherosclerosis. Current Opinion in Lipidology, 2016, 27, 592-596.	2.7	12
104	InÂVivo PET Imaging of HDL in MultipleÂAtherosclerosisÂModels. JACC: Cardiovascular Imaging, 2016, 9, 950-961.	5.3	78
105	Câ€Reactive Protein Identifies Lowâ€Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancerâ€"Norfolk Prospective Population Study. Journal of the American Heart Association, 2016, 5, .	3.7	23
106	Current therapies for lowering lipoprotein (a). Journal of Lipid Research, 2016, 57, 1612-1618.	4.2	77
107	Comparison of <scp>PCSK9</scp> Inhibitor Evolocumab vs Ezetimibe in Statinâ€Intolerant Patients: Design of the Goal Achievement After Utilizing an Antiâ€<scp>PCSK9</scp> Antibody in Statinâ€Intolerant Subjects 3 (<scp>GAUSS</scp>â€3) Trial. Clinical Cardiology, 2016, 39, 137-144.	1.8	32
108	Increasing the Spatial Resolution of 3T Carotid MRI Has No Beneficial Effect for Plaque Component Measurement Reproducibility. PLoS ONE, 2015, 10, e0130878.	2.5	8

#	Article	IF	Citations
109	Statin-associated muscle symptoms: impact on statin therapyâ€"European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	2.2	1,024
110	Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1133-1140.	3.3	37
111	Guideline treatment results in regression of atherosclerosis in type 2 diabetes mellitus. Diabetes and Vascular Disease Research, 2015, 12, 126-132.	2.0	4
112	Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Science Advances, 2015, 1, .	10.3	173
113	Effect of Anti-ApoA-I Antibody-Coating of Stents on Neointima Formation in a Rabbit Balloon-Injury Model. PLoS ONE, 2015, 10, e0122836.	2.5	6
114	The Effect of a Diiodothyronine Mimetic on Insulin Sensitivity in Male Cardiometabolic Patients: A Double-Blind Randomized Controlled Trial. PLoS ONE, 2014, 9, e86890.	2.5	30
115	Adrenal Function in Females with Low Plasma HDL-C Due to Mutations in ABCA1 and LCAT. PLoS ONE, 2014, 9, e90967.	2.5	12
116	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 2014, 35, 2146-2157.	2.2	835
117	Effects of an Antisense Oligonucleotide Inhibitor of Câ€Reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers. Journal of the American Heart Association, 2014, 3, .	3.7	33
118	HDL does not influence the polarization of human monocytes toward an alternative phenotype. International Journal of Cardiology, 2014, 172, 179-184.	1.7	23
119	Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. Journal of the American College of Cardiology, 2014, 63, 2541-2548.	2.8	465
120	Design and Rationale of the <scp>GAUSS</scp>â€2 Study Trial: A Doubleâ€Blind, Ezetimibeâ€Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (<scp>AMG</scp> 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy. Clinical Cardiology, 2014, 37, 131-139.	1.8	25
121	Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation inÂFamilial Hypercholesterolemia. Journal of the American College of Cardiology, 2014, 64, 1418-1426.	2.8	90
122	A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nature Communications, 2014, 5, 3065.	12.8	336
123	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology,the, 2014, 2, 655-666.	11.4	473
124	Carriers of Loss-of-Function Mutations in EXT Display Impaired Pancreatic Beta-Cell Reserve Due to Smaller Pancreas Volume. PLoS ONE, 2014, 9, e115662.	2.5	12
125	Hypertriglyceridemia: the future of genetics to guide individualized therapeutic strategies. Clinical Lipidology, 2013, 8, 321-328.	0.4	0
126	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	2.2	2,132

#	Article	IF	Citations
127	ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. European Heart Journal, 2013, 34, 286-291.	2.2	61
128	High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C. Journal of Lipid Research, 2013, 54, 1698-1704.	4.2	45
129	The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease. Current Pharmaceutical Design, 2013, 19, 3143-3149.	1.9	24
130	Novel anti-inflammatory strategies in atherosclerosis. Current Opinion in Lipidology, 2012, 23, 532-539.	2.7	39
131	PS3 - 15. Genetic Variation at the SULF2 Locus Affects Hepatic Postprandial Remnant Clearance in Patients with Type 2 Diabetes Mellitus. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 109-109.	0.0	0
132	PS14 - 68. Differential effects of antibiotics on bile acid metabolism, intestinal microbiota composition and insulin resistance in obese humans; a randomised controlled trial. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 147-147.	0.0	0
133	Lipid Oxidation in Carriers of Lecithin:Cholesterol Acyltransferase Gene Mutations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 3066-3075.	2.4	27
134	Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. Atherosclerosis, 2012, 225, 481-485.	0.8	31
135	Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. European Heart Journal, 2012, 33, 1142-1149.	2.2	171
136	Inhibition of hepatic sulfatase-2 In Vivo: A novel strategy to correct diabetic dyslipidemia. Hepatology, 2012, 55, 1746-1753.	7.3	37
137	Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis. Clinical Genetics, 2012, 81, 24-28.	2.0	14
138	Cholesterol Acyltransferase Gene Mutations Have Accelerated Atherogenesis as Assessed by Carotid 3.0-T Magnetic Resonance Imaging. Journal of the American College of Cardiology, 2011, 58, 2481-2487.	2.8	58
139	Physical activity, metabolic syndrome, and coronary risk: the EPICâ€"Norfolk prospective population study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 209-217.	2.8	46
140	Dalcetrapib: turning the tide for CETP inhibition?. Lancet, The, 2011, 378, 1529-1530.	13.7	1
141	Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia, 2010, 53, 2646-2655.	6.3	302
142	Comparison between Gradient Gel Electrophoresis and Nuclear Magnetic Resonance Spectroscopy in Estimating Coronary Heart Disease Risk Associated with LDL and HDL Particle Size. Clinical Chemistry, 2010, 56, 789-798.	3.2	36
143	Lipid Measures and Cardiovascular Disease Prediction. Disease Markers, 2009, 26, 209-216.	1.3	11
144	Safety and Tolerability of Dalcetrapibâ€â€Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Colu. American Journal of Cardiology, 2009, 104, 82-91.	1.6	134

#	Article	IF	Citations
145	The Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors. American Journal of Cardiology, 2009, 104, 32E-38E.	1.6	59
146	Biologic Effects of Simvastatin in Patients with Aneurysmal Subarachnoid Hemorrhage: A Double-Blind, Placebo-Controlled Randomized Trial. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1444-1453.	4.3	118
147	Dalcetrapib: no offâ€target toxicity on blood pressure or on genes related to the reninâ€angiotensinâ€aldosterone system in rats. British Journal of Pharmacology, 2009, 158, 1763-1770.	5.4	48
148	Comparison of In Vivo Carotid 3.0-T Magnetic Resonance to B-Mode Ultrasound Imaging and Histology in a Porcine Model. JACC: Cardiovascular Imaging, 2009, 2, 744-750.	5.3	8
149	In vivo glycocalyx degradation induces proteinuria and insulin resistance without affecting atherogenesis in apoE knockout mice on a Westernâ€type diet. FASEB Journal, 2009, 23, 950.5.	0.5	0
150	Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia, 2008, 51, 1081-1084.	6.3	62
151	Microthrombosis after Aneurysmal Subarachnoid Hemorrhage: An Additional Explanation for Delayed Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1761-1770.	4.3	289
152	Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. New England Journal of Medicine, 2008, 358, 1431-1443.	27.0	1,180
153	Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability. Journal of Applied Physiology, 2008, 104, 845-852.	2.5	170
154	Sulfated glycosaminoglycans restore glycocalyx barrier properties of cultured endothelial cells in hyperglycemia. FASEB Journal, 2008, 22, 83-83.	0.5	6
155	Role of the Apolipoprotein Bâ€"Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Caseâ€"Control Analysis in EPIC-Norfolk. Annals of Internal Medicine, 2007, 146, 640.	3.9	140
156	Antisense Apolipoprotein B-100 As Novel Treatment For Hypercholesterolemia: Focus On Isis 301012. Future Lipidology, 2007, 2, 387-393.	0.5	6
157	High-Density Lipoprotein Attenuates Inflammation and Coagulation Response on Endotoxin Challenge in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1153-1158.	2.4	102
158	Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. Diabetologia, 2007, 50, 1288-1293.	6.3	80
159	Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients. Antiviral Therapy, 2007, 12, 1127-1132.	1.0	64
160	Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles?. Cardiovascular Research, 2006, 69, 341-347.	3.8	45
161	Lipoprotein Lipase S447X. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1236-1245.	2.4	140
162	Loss of Endothelial Glycocalyx During Acute Hyperglycemia Coincides With Endothelial Dysfunction and Coagulation Activation In Vivo. Diabetes, 2006, 55, 480-486.	0.6	469

#	Article	IF	Citations
163	Endothelial Glycocalyx Damage Coincides With Microalbuminuria in Type 1 Diabetes. Diabetes, 2006, 55, 1127-1132.	0.6	361
164	Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans. Circulation Research, 2005, 96, 714-716.	4.5	208
165	Letter Regarding Article by Luo et al, â€œAdenovirus-Mediated Expression of Î²-Adrenergic Receptor Kinase C-Terminus Reduces Intimal Hyperplasia and Luminal Stenosis of Arteriovenous Polytetrafluoroethylene Grafts in Pigsâ€• Circulation, 2005, 112, e153; author reply e153.	1.6	1
166	Statins and LDLâ€cholesterol lowering: an overview. Current Medical Research and Opinion, 2005, 21, S9-S16.	1.9	45
167	Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. Journal of the American College of Cardiology, 2005, 45, 185-197.	2.8	402
168	A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. Journal of the American College of Cardiology, 2004, 44, 1429-1435.	2.8	124
169	Restoration of Endothelial Function by Increasing High-Density Lipoprotein in Subjects With Isolated Low High-Density Lipoprotein. Circulation, 2003, 107, 2944-2948.	1.6	283
170	Measurement of subclinical atherosclerosis: beyond risk factor assessment. Current Opinion in Lipidology, 2002, 13, 595-603.	2.7	37
171	Ferric saccharate induces oxygen radical stress and endothelial dysfunction inÂvivo. European Journal of Clinical Investigation, 2002, 32, 9-16.	3.4	129
172	Folic Acid Reverts Dysfunction of Endothelial Nitric Oxide Synthase. Circulation Research, 2000, 86, 1129-1134.	4.5	265
173	Influence of Folic Acid on Postprandial Endothelial Dysfunction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 185-188.	2.4	150
174	Nitric oxide and hypercholesterolemia: a matter of oxidation and reduction?. Atherosclerosis, 1998, 137, S51-S60.	0.8	51
175	Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?. Cardiovascular Research, 1998, 39, 543-549.	3.8	9